Dendreon (DNDN) Takes a Downer as ZYTIGA Makes News
Tweet Send to a Friend
Get Alerts DNDN Hot Sheet
Down)
Trade DNDN Now!
After a speculation-fueled run-up so far this week, Dendreon Corp. (Nasdaq: DNDN) is weaker Friday as news on competing drug ZYTIGA takes the spotlight.
Today, Johnson & Johnson's (NYSE: JNJ) Janssen-Cilag unit announced that it submitted a type II variation to the European Medicines Agency (EMA) for ZYTIGA. In addition, they submitted a supplemental New Drug Application (sNDA) to the U.S. FDA.
Shares of DNDN are down 1 percent early Friday, but still up 19 percent on the week. Most of the upside can be attributed to unconfirmed takeover speculation and a new Buy rating.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Today, Johnson & Johnson's (NYSE: JNJ) Janssen-Cilag unit announced that it submitted a type II variation to the European Medicines Agency (EMA) for ZYTIGA. In addition, they submitted a supplemental New Drug Application (sNDA) to the U.S. FDA.
Shares of DNDN are down 1 percent early Friday, but still up 19 percent on the week. Most of the upside can be attributed to unconfirmed takeover speculation and a new Buy rating.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Tesla (TSLA) Ramps Higher (GM)
- UPDATE: MannKind Corp. (MNKD) Crashes
- Mediabistro (MBIS) Surges, But No One Knows Why
Create E-mail Alert Related Categories
Trader Talk
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
